glp-1 medication competitors pharmaceutical companies Agonists Weight Loss Drugs Market Report, 2025-2030 Market Overview: GLP-1 Agonists and

Novo Nordisk is advancing CagriSema toward commercial launch while also developing amycretin, a single-molecule dual GLP-1/amylin agonist that could eventually replace the two-injection CagriSema protocol with a single compound

They already make the most potent weight-loss medication out there, Low Wang said, referring to Zepbound and Mounjaro

The effects of subcutaneous deferoxamine administration on renal function in thalassemia major

Adherence to the prescribed dosage and attending follow-up appointments with healthcare providers for monitoring and potential treatment adjustments are crucial components for successful outcomes